scholarly journals Early class III treatment decision-making

2019 ◽  
Vol 9 ◽  
pp. 68-72
Author(s):  
Peter Ngan ◽  
David Musich

Clinicians make decisions for their patients everyday. Ryan Hamilton, in his course guidebook, How You Decide: The Science of Human Decision Making, summarized the current research on the 4 R's of decision-making that matter: reference points, reasons, resources, and replacement. The authors will apply this principle in the decision- making necessary for the growing Class III patients. First, the decision on whether to treat or not to treat Class III patients in the mixed dentition rely on a thorough diagnosis and objectives for early treatment. For example, elimination of a functional shift of the mandible may be a good reason to institute early treatment. Second, the decision on when to start Phase II treatment relies on the follow-up observation after Phase I treatment. The authors suggested the use of a “checklist” to decide whether patient will be benefited from surgical intervention or nonsurgical orthodontic treatment. If the checklist review has several negative checkpoints, it will help the clinicians to decide on an aggressive stage of 4–8 months therapeutic re-diagnosis to confirm the surgical or nonsurgical decision.

2013 ◽  
Vol 47 (11) ◽  
pp. 1700-1707 ◽  
Author(s):  
Daniel Lucas da Conceição Costa ◽  
Roseli Gedanke Shavitt ◽  
Raony Cassab Castro Cesar ◽  
Marinês Alves Joaquim ◽  
Sonia Borcato ◽  
...  

2017 ◽  
Vol 13 (2) ◽  
pp. 169-184 ◽  
Author(s):  
Shuya Kushida ◽  
Takeshi Hiramoto ◽  
Yuriko Yamakawa

In spite of increasing advocacy for patients’ participation in psychiatric decision-making, there has been little research on how patients actually participate in decision-making in psychiatric consultations. This study explores how patients take the initiative in decision-making over treatment in outpatient psychiatric consultations in Japan. Using the methodology of conversation analysis, we analyze 85 video-recorded ongoing consultations and find that patients select between two practices for taking the initiative in decision-making: making explicit requests for a treatment and displaying interest in a treatment without explicitly requesting it. A close inspection of transcribed interaction reveals that patients make explicit requests under the circumstances where they believe the candidate treatment is appropriate for their condition, whereas they merely display interest in a treatment when they are not certain about its appropriateness. By fitting practices to take the initiative in decision-making with the way they describe their current condition, patients are optimally managing their desire for particular treatments and the validity of their initiative actions. In conclusion, we argue that the orderly use of the two practices is one important resource for patients’ participation in treatment decision-making.


2007 ◽  
Author(s):  
Mary A. O'Brien ◽  
Timothy Whelan ◽  
Amiram Gafni ◽  
Cathy Charles ◽  
Peter Ellis

2020 ◽  
Vol 27 (17) ◽  
pp. 2826-2839 ◽  
Author(s):  
Roberta Caputo ◽  
Daniela Cianniello ◽  
Antonio Giordano ◽  
Michela Piezzo ◽  
Maria Riemma ◽  
...  

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).


Sign in / Sign up

Export Citation Format

Share Document